Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.
The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.
The company defends its cancer strategy, and says it's not a me-too developer.